Cerus announces additional DoD award to advance hemorrhage care

Cerus (CERS) Corporation announced it has been awarded an additional $7.2M contract amendment by the U.S. Department of Defense Industrial Base Analysis and Sustainment program for the development of lyophilized INTERCEPT Fibrinogen Complex, or IFC, to treat bleeding due to trauma. The additional funding will support CRYO-FIRST, a randomized study comparing the use of pre-thawed IFC to conventional cryoprecipitated antihemophilic factor in trauma-associated hemorrhagic shock patients. This is additive to the approximately $18M currently provided under Cerus’ contract with the DoD.